title: [Leprosy reactions in a Colombian national reference centre].
abstract: BACKGROUND
  Colombia is the country in America with the highest proportion of new cases leprosy with severe disability. To decrease such disability it is necessary to control these reactions, the main cause of nerve damage in leprosy.
  
  
  OBJECTIVE
  To describe the clinical and epidemiological characteristics and the treatment of patients with type 1 and 2 leprosy reactions who consulted the Centro Dermatológico Federico Lleras Acosta.
  
  
  METHODS
  It is a descriptive study which included patients with clinical diagnoses of type 1 and 2 reactions who were seen in the center between 2003 and 2009. The town of origin of the patients, their age, clinical features and treatments were analysed.
  
  
  RESULTS
  We studied 96 reactions in 87 patients, 35 type 1 and 61 type 2 reactions; 75% of the patients came from the departments of Tolima, Cundinamarca, Santander and Boyacá; 77% of type 1 reaction occurred before the beginning of multidrug therapy for leprosy. The reactions that started after stopping the multidrug therapy were considered as a leprosy relapse.
  
  
  CONCLUSIONS
  Correct identification of type 1 reaction by the general practitioner will allow the diagnosis of leprosy in a large percentage of patients. The type 1 reaction that begins after stopping the leprosy multidrug therapy may be a manifestation of a relapse of the disease.
authors.affiliation: Centro Dermatológico Federico Lleras Acosta, E.S.E, Bogotá, D.C., Colombia. johnnovavilla@yahoo.com
authors.forename: John
authors.initials: J
authors.lastname: Nova
authors.forename: Guillermo
authors.initials: G
authors.lastname: Sánchez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003105:Colombia / Q000453:epidemiology; D016207:Cytokines / Q000378:metabolism; D004359:Drug Therapy, Combination; D004893:Erythema Nodosum / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D007105:Immune Complex Diseases / Q000453:epidemiology / Q000209:etiology; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology* / Q000503:physiopathology; D015440:Leprosy, Lepromatous / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D056005:Leprosy, Paucibacillary / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D016207:Cytokines; D007917:Leprostatic Agents